0	3	The	the	DT
4	7	p53	p53	NN
8	15	paradox	paradox	NN
16	18	in	in	IN
19	22	the	the	DT
23	35	pathogenesis	pathogenesis	NN
36	38	of	of	IN
39	44	tumor	tumor	NN
45	56	progression	progression	NN
56	57	.	.	.

59	65	Recent	recent	JJ
66	74	evidence	evidence	NN
75	83	suggests	suggest	VBZ
84	88	that	that	IN
89	92	the	the	DT
93	96	p53	p53	NN
97	105	molecule	molecule	NN
106	113	appears	appear	VBZ
114	116	in	in	IN
117	120	two	two	CD
121	130	different	different	JJ
131	136	forms	form	NNS
136	137	:	:	:
138	141	the	the	DT
142	148	mutant	mutant	JJ
149	152	p53	p53	NN
153	157	that	that	WDT
158	168	stimulates	stimulate	VBZ
169	174	tumor	tumor	NN
175	186	progression	progression	NN
186	187	,	,	,
188	191	and	and	CC
192	196	wild	wild	JJ
197	201	type	type	NN
202	205	p53	p53	NN
206	210	that	that	WDT
211	219	inhibits	inhibit	VBZ
220	225	tumor	tumor	NN
226	237	progression	progression	NN
237	238	.	.	.

239	241	In	in	IN
242	250	addition	addition	NN
250	251	,	,	,
252	254	it	it	PRP
255	258	has	have	VBZ
259	263	been	be	VBN
264	275	established	establish	VBN
276	280	that	that	IN
281	286	tumor	tumor	NN
287	295	necrosis	necrosis	NN
296	308	factor-alpha	factor-alpha	NN
309	310	(	(	(
310	319	TNF-alpha	TNF-alpha	NNP
319	320	)	)	)
321	324	can	can	MD
325	333	activate	activate	VB
334	337	the	the	DT
338	348	expression	expression	NN
349	351	of	of	IN
352	356	wild	wild	JJ
357	361	type	type	NN
362	365	p53	p53	NN
366	368	in	in	IN
369	376	concert	concert	NN
377	381	with	with	IN
382	385	the	the	DT
386	393	nuclear	nuclear	JJ
394	407	transcription	transcription	NN
408	414	factor	factor	NN
414	415	,	,	,
416	424	NF-kappa	NF-kappa	NNP
425	427	B.	B.	NNP
428	432	Both	both	CC
433	442	TNF-alpha	TNF-alpha	NNP
443	446	and	and	CC
447	455	NF-kappa	NF-kappa	NNP
456	457	B	B	NNP
458	461	are	be	VBP
462	466	also	also	RB
467	475	involved	involve	VBN
476	478	in	in	IN
479	482	the	the	DT
483	494	stimulation	stimulation	NN
495	497	of	of	IN
498	501	the	the	DT
502	509	pathway	pathway	NN
510	514	that	that	WDT
515	520	leads	lead	VBZ
521	523	to	to	TO
524	527	the	the	DT
528	538	expression	expression	NN
539	541	of	of	IN
542	547	major	major	JJ
548	566	histocompatibility	histocompatibility	NN
567	574	complex	complex	NN
575	576	(	(	(
576	579	MHC	MHC	NNP
579	580	)	)	)
581	586	class	class	NN
587	588	I	i	CD
589	598	molecules	molecule	NNS
599	602	and	and	CC
602	603	,	,	,
604	609	hence	hence	RB
609	610	,	,	,
611	618	antigen	antigen	NN
619	631	presentation	presentation	NN
632	634	to	to	TO
635	638	the	the	DT
639	640	T	t	NN
641	646	cells	cell	NNS
646	647	.	.	.

648	650	In	in	IN
651	655	this	this	DT
656	661	paper	paper	NN
662	664	we	we	PRP
665	670	shall	shall	MD
671	678	advance	advance	VB
679	682	the	the	DT
683	693	hypothesis	hypothesis	NN
694	698	that	that	IN
698	699	:	:	:
700	701	(	(	(
701	702	i	i	LS
702	703	)	)	)
704	713	TNF-alpha	TNF-alpha	NNP
714	724	indirectly	indirectly	RB
725	733	controls	control	VBZ
734	740	immune	immune	JJ
741	753	surveillance	surveillance	NN
753	754	;	;	:
755	758	and	and	CC
759	760	(	(	(
760	762	ii	ii	LS
762	763	)	)	)
764	773	TNF-alpha	TNF-alpha	NNP
774	782	controls	control	VBZ
783	786	DNA	dna	NN
787	793	repair	repair	NN
794	797	and	and	CC
798	803	tumor	tumor	NN
804	815	suppression	suppression	NN
816	823	through	through	IN
824	827	the	the	DT
828	838	regulation	regulation	NN
839	841	of	of	IN
842	846	wild	wild	JJ
847	851	type	type	NN
852	855	p53	p53	NN
855	856	.	.	.

857	861	Thus	thus	RB
861	862	,	,	,
863	865	it	it	PRP
866	868	is	be	VBZ
869	881	hypothesized	hypothesize	VBN
882	886	that	that	IN
887	895	elevated	elevated	JJ
896	905	TNF-alpha	TNF-alpha	NNP
906	908	is	be	VBZ
909	918	primarily	primarily	RB
919	930	responsible	responsible	JJ
931	934	for	for	IN
935	944	promoting	promote	VBG
945	950	tumor	tumor	NN
951	962	progression	progression	NN
962	963	.	.	.